GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Aridis Pharmaceuticals ARDS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 5 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Aridis Pharmaceuticals — daily ARDS Delayed
Market value
$3,755
Last close × shares
Volume
1k
Shares, 5 Nov 2026

About Aridis Pharmaceuticals

Its shares trade under the ticker ARDS. It has been listed since 14 August 2018. In the fiscal year to 31 December 2022, it reported revenue of $19.3m and a net loss of $30.7m. At that date it held total assets of $14.7m and shareholders' equity of −$24.2m.

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. The company is headquartered in Los Gatos, California. The company went IPO on 2018-08-14. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.

Figures and description from our data supplier, not checked against the company's own report.

More about Aridis Pharmaceuticals →

Latest on Aridis Pharmaceuticals

Our reporting

We have not reported on Aridis Pharmaceuticals yet.

Next results

3 Mar 2027

Due on 3 Mar 2027. Analysts expect earnings of -0.63 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Aridis Pharmaceuticals's ticker?

Aridis Pharmaceuticals trades as ARDS on its US listing, under ISIN US0403341045.

What was Aridis Pharmaceuticals's last closing price?

0.00 on 5 Nov 2026. The figure is in USD and is never converted.

When does Aridis Pharmaceuticals next report results?

Results are expected on 3 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.